Key result
Elevated Pentraxin 3 plasma levels 24 hours after bare-metal stent implantation for STEMI were independently associated with an increased risk of major adverse cardiovascular events (RR 2.402).
Why the study?
The study was conducted to assess the prognostic value of pentraxin 3 in patients with STEMI after bare-metal stent implantation.
Does elevated pentraxin 3 (PTX3) at 24 hours predict major adverse cardiovascular events in patients with STEMI after bare-metal stent implantation?
Observational (n=97)
No
Does elevated pentraxin 3 (PTX3) at 24 hours predict major adverse cardiovascular events in patients with STEMI after bare-metal stent implantation?
Relative Risk: 2.402 (95% CI 1.392–4.286)
Absolute Event Rate: 30.4% vs 9.8%
p-value: p=<0.001
Pentraxin 3 measured 24 hours after bare-metal stent implantation in STEMI patients is a strong, independent predictor of long-term major adverse cardiovascular events, outperforming traditional markers like hsCRP.
Should not yet change post-STEMI risk assessment after BMS; leaves open PTX3 as a prognostic marker pending larger prospective studies.
OBJECTIVES: To assess the prognostic value of pentraxin 3 (PTX3) in patients with ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation. METHODS: In this prospective study, PTX3, interleukin (IL-6), IL-10, high-sensitivity c-reactive protein (hsCRP), and cardiac troponin I (cTnI) plasma values were determined before and 24 hours after BMS implantation in 97 consecutively enrolled patients with STEMI who were admitted to University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina between February 2016 and February 2017. Patients were followed for 24 months to assess major adverse cardiovascular events (MACEs). RESULTS: At 24 hours after percutaneous coronary intervention (PCI), plasma values of PTX3, IL-6, hsCRP, and cTnI were significantly increased; and IL-10 levels were significantly decreased compared with the values determined before PCI. Patients with MACEs had significantly higher plasma PTX3 levels at 24 hours after BMS-PCI than in patients without MACEs. Patients with PTX3 plasma values ≥5042 ng/ml had a significantly higher risk of MACEs than patients with PTX3 levels <5.042 ng/mL. Pentraxin 3 levels exhibited strong and significant correlations with IL-6 and IL-10 levels. Pentraxin 3, cTnI, and IL-6, but not hsCRP levels have showed independent association with MACEs, according to the multivariate Cox regression analysis. CONCLUSION: Pentraxin 3 might be better serum prognostic marker than IL-6, IL-10 or high sensitivity CRP for MACEs after BMS-PCI. It might help to make better risk stratification of those patients who are undergoing BMS-PCI.
No takes yet. Share an insight, caveat, or question.
Ljuca et al. (2019) conducted an observational in ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation (n=97). Elevated Pentraxin 3 (PTX3) plasma levels vs. Lower Pentraxin 3 (PTX3) plasma levels was evaluated on Major adverse cardiovascular events (MACEs) (RR 2.402, 95% CI 1.392-4.286, p=<0.001). Elevated Pentraxin 3 plasma levels 24 hours after bare-metal stent implantation for STEMI were independently associated with an increased risk of major adverse cardiovascular events (RR 2.402).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: